Dexcom said Q4 2024 revenue grew 8% year-over-year to $1.114 billion on a reported basis, and full-year 2024 revenue grew 11% versus the prior year to $4.033 billion.

1. 01

   Dexcom said Q4 2024 revenue grew 8% year-over-year to $1.114 billion on a reported basis, and full-year 2024 revenue grew 11% versus the prior year to $4.033 billion.

2. 02

   The company said GAAP operating income for Q4 2024 was $188.9 million, or 17.0% of revenue, a decrease of 400 basis points compared to Q4 2023. GAAP net income for the same quarter was $151.7 million, or $0.38 per diluted share.

3. 03

   Dexcom said non-GAAP operating income for full year 2024 was $757.1 million, or 18.8% of revenue, a decrease of 100 basis points compared to the prior year. Full-year GAAP operating income was $600.0 million, or 14.9% of revenue.

4. 04

   The company said it held $2.58 billion in cash, cash equivalents and marketable securities as of December 31, 2024. For full-year 2025 guidance, Dexcom provided revenue of $4.60 billion (14% growth) and Adjusted EBITDA Margin of approximately 30%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.